-
公开(公告)号:ID24653A
公开(公告)日:2000-07-27
申请号:ID991048
申请日:1998-03-09
Applicant: BASF AG
Inventor: CALDERWOOD DAVID JOHN , JOHNSTON DAVID NORMAN , RAFFERTY PAUL , TWIGGER HELEN LOUISE , MUNSCHAUER RAINER , ARNOLD LEE
IPC: A61K31/519 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , A61K31/505
Abstract: Compounds of formula I including pharmaceutically acceptable salts thereof in which R1 represents hydrogen, 2-phenyl-1,3-dioxan-5-yl, a C1-6 alkyl group, a C3-8 cycloalkyl group, a C5-7 cycloalkenyl group or an (optionally substituted phenyl)C1-6 alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substituted by one or more groups of formula ORA in which RA represents H or a C1-6 alkyl group provided that a group of formula ORA is not located on the carbon attached to nitrogen; R2 represents hydrogen, a C1-6 alkyl group, a C3-8 cycloalkyl group, halo, hydroxy, an (optionally substituted phenyl)C1-6 alkyl group, optionally substituted phenyl or R4; and R3 represents a group of formula (a) in which the phenyl ring is additionally optionally substituted and A represents NH, O, NHSO2, SO2NH, a C1-4 alkylene chain, NHCO, NHCO2, CONH, NHCONH, CO2 or S(O)p in which p is 0, 1 or 2, or A is absent and R5 is attached directly to the phenyl ring; and R5 represents optionally substituted phenyl and, additionally, when A is absent R5 represents a) a phthalimido group optionally substituted by halo or b) a pyrazolylamino group in which the pyrazole ring is optionally substituted by one or more of the following: hydroxy or optionally substituted phenyl; R4 represents a heterocyclic group; are described which are useful in treating proliferative diseases and disorders of the immune system in mammals. Processes to prepare these compounds and pharmaceutical compositions containing these compound are also described.
-
公开(公告)号:CZ9903283A3
公开(公告)日:2000-03-15
申请号:CZ328399
申请日:1998-03-09
Applicant: BASF AG
Inventor: CALDERWOOD DAVID JOHN , JOHNSTON DAVID NORMAN , RAFFERTY PAUL , TWIGGER HELEN LOUISE , MUNSCHAUER RAINER , ARNOLD LEE
IPC: A61K31/505 , A61P37/00 , C07D209/00 , C07D239/00 , C07D487/04
-
公开(公告)号:CZ328399A3
公开(公告)日:2000-03-15
申请号:CZ328399
申请日:1998-03-09
Applicant: BASF AG
Inventor: CALDERWOOD DAVID JOHN , JOHNSTON DAVID NORMAN , RAFFERTY PAUL , TWIGGER HELEN LOUISE , MUNSCHAUER RAINER , ARNOLD LEE
IPC: A61K31/505 , A61P37/00 , C07D209/00 , C07D239/00 , C07D487/04
-
公开(公告)号:TR9902301T2
公开(公告)日:1999-12-21
申请号:TR9902301
申请日:1998-03-09
Applicant: BASF AG
Inventor: CALDERWOOD DAVID JOHN , JOHNSTON DAVID NORMAN , RAFFERTY PAUL , TWIGGER HELEN LOUISE , MUNSCHAUER DR RAINER , ARNOLD LEE
IPC: A61K31/519 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04
CPC classification number: C07D487/04
-
公开(公告)号:NO994509D0
公开(公告)日:1999-09-17
申请号:NO994509
申请日:1999-09-17
Applicant: BASF AG
Inventor: CALDERWOOD DAVID JOHN , JOHNSTON DAVID NORMAN , RAFFERTY PAUL , TWIGGER HELEN LOUISE , MUNSCHAUER RAINER , ARNOLD LEO
IPC: A61K31/519 , A61P35/00 , A61P37/02 , A61P43/00 , C07D487/04 , C07D
Abstract: Compounds of formula I including pharmaceutically acceptable salts thereof in which R1 represents hydrogen, 2-phenyl-1,3-dioxan-5-yl, a C1-6 alkyl group, a C3-8 cycloalkyl group, a C5-7 cycloalkenyl group or an (optionally substituted phenyl)C1-6 alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substituted by one or more groups of formula ORA in which RA represents H or a C1-6 alkyl group provided that a group of formula ORA is not located on the carbon attached to nitrogen; R2 represents hydrogen, a C1-6 alkyl group, a C3-8 cycloalkyl group, halo, hydroxy, an (optionally substituted phenyl)C1-6 alkyl group, optionally substituted phenyl or R4; and R3 represents a group of formula (a) in which the phenyl ring is additionally optionally substituted and A represents NH, O, NHSO2, SO2NH, a C1-4 alkylene chain, NHCO, NHCO2, CONH, NHCONH, CO2 or S(O)p in which p is 0, 1 or 2, or A is absent and R5 is attached directly to the phenyl ring; and R5 represents optionally substituted phenyl and, additionally, when A is absent R5 represents a) a phthalimido group optionally substituted by halo or b) a pyrazolylamino group in which the pyrazole ring is optionally substituted by one or more of the following: hydroxy or optionally substituted phenyl; R4 represents a heterocyclic group; are described which are useful in treating proliferative diseases and disorders of the immune system in mammals. Processes to prepare these compounds and pharmaceutical compositions containing these compound are also described.
-
-
-
-